OMERS ADMINISTRATION Corp Sells 5,211 Shares of Humana Inc. $HUM

Key Points

• OMERS Administration Corp reduced its stake in Humana Inc. by 14.5%, now owning a total of 30,682 shares worth approximately $8.12 million.
• Humana's latest quarterly earnings miss consensus estimates, reporting $6.27 EPS against an expected $6.32, while revenue was $32.39 billion, surpassing projections.
• The company declared a quarterly dividend of $0.885 per share, resulting in an annual yield of 1.2%, with the payment date set for October 31.

OMERS ADMINISTRATION Corp lowered its holdings in shares of Humana Inc. (NYSE:HUM - Free Report) by 14.5% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 30,682 shares of the insurance provider's stock after selling 5,211 shares during the quarter. OMERS ADMINISTRATION Corp's holdings in Humana were worth $8,118,000 at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of HUM. Vanguard Group Inc. raised its position in shares of Humana by 8.9% during the first quarter. Vanguard Group Inc. now owns 13,972,872 shares of the insurance provider's stock worth $3,697,222,000 after purchasing an additional 1,143,662 shares during the period. GAMMA Investing LLC raised its position in shares of Humana by 40,881.1% during the first quarter. GAMMA Investing LLC now owns 781,099 shares of the insurance provider's stock worth $2,066,790,000 after purchasing an additional 779,193 shares during the period. Southpoint Capital Advisors LP acquired a new stake in shares of Humana during the fourth quarter worth about $190,282,000. Nuveen LLC acquired a new stake in shares of Humana during the first quarter worth about $171,220,000. Finally, Dodge & Cox raised its position in shares of Humana by 5.5% during the first quarter. Dodge & Cox now owns 10,755,215 shares of the insurance provider's stock worth $2,845,830,000 after purchasing an additional 557,175 shares during the period. Institutional investors and hedge funds own 92.38% of the company's stock.

Humana Stock Down 0.5%

HUM stock traded down $1.44 during mid-day trading on Wednesday, reaching $308.62. The company had a trading volume of 413,875 shares, compared to its average volume of 1,698,333. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.95 and a quick ratio of 1.95. The stock has a 50 day simple moving average of $257.24 and a two-hundred day simple moving average of $255.32. The company has a market capitalization of $37.12 billion, a price-to-earnings ratio of 23.70, a PEG ratio of 1.79 and a beta of 0.44. Humana Inc. has a 52 week low of $206.87 and a 52 week high of $382.72.

Humana (NYSE:HUM - Get Free Report) last posted its quarterly earnings results on Wednesday, July 30th. The insurance provider reported $6.27 earnings per share for the quarter, missing analysts' consensus estimates of $6.32 by ($0.05). The company had revenue of $32.39 billion during the quarter, compared to the consensus estimate of $31.85 billion. Humana had a net margin of 1.28% and a return on equity of 13.67%. The firm's revenue for the quarter was up 9.6% compared to the same quarter last year. During the same quarter in the prior year, the business earned $6.96 earnings per share. Humana has set its FY 2025 guidance at 17.000- EPS. As a group, equities analysts predict that Humana Inc. will post 16.47 earnings per share for the current fiscal year.

Humana Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Friday, September 26th will be paid a $0.885 dividend. This represents a $3.54 dividend on an annualized basis and a yield of 1.1%. The ex-dividend date is Friday, September 26th. Humana's dividend payout ratio (DPR) is currently 27.17%.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the company. Morgan Stanley decreased their price objective on Humana from $290.00 to $277.00 and set an "equal weight" rating for the company in a report on Thursday, July 31st. Wells Fargo & Company decreased their price objective on Humana from $348.00 to $344.00 and set an "overweight" rating for the company in a report on Thursday, August 14th. Truist Financial decreased their price objective on Humana from $280.00 to $260.00 and set a "hold" rating for the company in a report on Wednesday, July 16th. Bank of America increased their price objective on Humana from $285.00 to $312.00 and gave the stock a "neutral" rating in a report on Tuesday. Finally, Barclays set a $275.00 price objective on Humana and gave the stock an "equal weight" rating in a report on Thursday, July 31st. Seven analysts have rated the stock with a Buy rating and sixteen have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, Humana presently has a consensus rating of "Hold" and an average target price of $285.76.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.